Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor vs Clopidogrel in Clopidogrel-Resistant OPCAB
NCT05166538Phase 4Unknown
- Sponsor
- Yonsei University
- Start
- Feb 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ticagrelor in coronary artery disease (CAD) (2 arms), sponsored by Yonsei University. Primary endpoint: Early graft patency at 1 year. Status: unknown.
02
Drugs
ticagrelor
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT05166538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05166538.